Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
In this section, you can review HDL cholesterol increase results from comparative clinical trials in which CRESTOR® (rosuvastatin calcium) was used as an adjunct to diet in patients who started statin therapy and in patients who switched statin therapy.
See how CRESTOR compares to other statins in raising HDL-cholesterol.
Click on the "+" and "—" signs to expand and collapse the clinical information.
‡Subject to eligibility. Restrictions apply. Click here for eligibility information.
HDL-C increases vs atorvastatin in hypercholesterolemic patients with CHD, 10-year CHD risk score >20% (CHD risk equivalent), or clinical evidence of atherosclerosis1
Adapted from the ECLIPSE Trial
Changes in HDL-C in patients who switched to CRESTOR vs remaining on simvastatin or atorvastatin2
Adapted from the MERCURY I Trial
HDL-C increases by dose in patients with hyperlipidemia or mixed dyslipidemia treated with CRESTOR vs other statins3,4
Adapted from the STELLAR Trial
HDL-C increases after switching to CRESTOR vs remaining on simvastatin in hypercholesterolemic patients with CHD, established atherosclerotic disease, diabetes, or a 10-year CHD risk >20%5
Adapted from the MERCURY II Trial
Lipitor is a registered trademark of Pfizer Inc.
You may report side effects related to AstraZeneca products by clicking here.